Integra Lifesciences Q2 2024 Adj EPS $0.63 Beats $0.62 Estimate, Sales $418.175M Beat $413.154M Estimate
Portfolio Pulse from Benzinga Newsdesk
Integra Lifesciences reported Q2 2024 adjusted EPS of $0.63, beating the estimate of $0.62. Sales were $418.175 million, surpassing the expected $413.154 million.
July 29, 2024 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Integra Lifesciences reported better-than-expected Q2 2024 results with an adjusted EPS of $0.63 and sales of $418.175 million, both surpassing estimates.
The better-than-expected earnings and sales figures are likely to positively impact Integra Lifesciences' stock price in the short term as they indicate strong financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100